- Home
- MASS vs IGMS Comparison
MASS vs IGMS Comparison
Compare MASS & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASS
- IGMS
- Stock Information
- Founded
- MASS 2012
- IGMS 1993
- Country
- MASS United States
- IGMS United States
- Employees
- MASS N/A
- IGMS N/A
- Industry
- MASS Medical/Dental Instruments
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- MASS Health Care
- IGMS Health Care
- Exchange
- MASS Nasdaq
- IGMS Nasdaq
- Market Cap
- MASS 84.3M
- IGMS 82.1M
- IPO Year
- MASS 2020
- IGMS 2019
- Fundamental
- Price
- MASS $6.90
- IGMS $1.36
- Analyst Decision
- MASS Buy
- IGMS Hold
- Analyst Count
- MASS 3
- IGMS 8
- Target Price
- MASS $5.33
- IGMS $6.00
- AVG Volume (30 Days)
- MASS 699.4K
- IGMS 1.2M
- Earning Date
- MASS 08-05-2025
- IGMS 08-13-2025
- Dividend Yield
- MASS N/A
- IGMS N/A
- EPS Growth
- MASS N/A
- IGMS N/A
- EPS
- MASS N/A
- IGMS N/A
- Revenue
- MASS $63,986,000.00
- IGMS $2,681,000.00
- Revenue This Year
- MASS N/A
- IGMS $134.30
- Revenue Next Year
- MASS $22.44
- IGMS $22.37
- P/E Ratio
- MASS N/A
- IGMS N/A
- Revenue Growth
- MASS 32.85
- IGMS 27.36
- 52 Week Low
- MASS $1.81
- IGMS $0.92
- 52 Week High
- MASS $8.06
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- MASS 53.47
- IGMS 60.17
- Support Level
- MASS $6.33
- IGMS $1.12
- Resistance Level
- MASS $7.27
- IGMS $1.38
- Average True Range (ATR)
- MASS 0.44
- IGMS 0.06
- MACD
- MASS -0.05
- IGMS 0.02
- Stochastic Oscillator
- MASS 45.60
- IGMS 90.32
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.